Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

NCT03744676 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT03744676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03744676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2018
Completion date
September 22, 2023
Enrollment
104 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

immune system disorder, immunoproliferative disorders, lymphatic diseases, lymphoma, lymphoma, b-cell, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, lymphoproliferative disorders, neoplasms, neoplasms by histologic type